EXPEDITED REVIEW
The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS)
Erick Schampaert, MD*,*,
Eric A. Cohen, MD ,
Michael Schlüter, PhD ,
François Reeves, MD ,
Mouhieddin Traboulsi, MD||,
Lawrence M. Title, MD¶,
Richard E. Kuntz, MD, MSc, FACC#,
Jeffrey J. Popma, MD, FACC# the C-SIRIUS Investigators
* Hôpital du Sacré-Coeur de Montréal, Montreal, Canada
Sunnybrook and Women's College Health Sciences Centre, Toronto, Canada
Center for Cardiology and Vascular Intervention, Hamburg, Germany
Centre Hospitalier de l'Université de Montréal, Pavillon Notre-Dame, Montreal, Canada
|| Calgary Heart Centre, Calgary, Canada
¶ Queen Elizabeth II Health Science Centre, Halifax, Nova Scotia, Canada
# Brigham and Women's Hospital, Boston, Massachusetts, USA
Manuscript received November 6, 2003;
revised manuscript received January 6, 2004,
accepted January 12, 2004.
* Reprint requests and correspondence: Dr. Erick Schampaert, Hôpital du Sacré-Coeur de Montréal, 5400 Bl. Gouin O., Montréal, Québec, Canada H4J 1C5.
erick.schampaert.hsc{at}ssss.gouv.qc.ca
OBJECTIVES: We assessed the safety and effectiveness of the sirolimus-eluting stent (SES) in treating single de novo long lesions in small native coronary arteries compared to an identical bare metal stent (BMS).
BACKGROUND: The SES was previously demonstrated to reduce restenosis significantly. However, patients with long lesions in small vessels have not been well studied and may define a group at very high risk.
METHODS: The Canadian Study of the Sirolimus-Eluting Stent in the Treatment of Patients With Long De Novo Lesions in Small Native Coronary Arteries (C-SIRIUS) was a multicenter, randomized, double-blind trial comparing SES versus identical BMS. The primary end point was in-stent minimal lumen diameter (MLD) at eight months. Secondary end points included angiographic restenosis at 8 months, target lesion revascularization (TLR), and major adverse cardiac events (MACE) at 270 days.
RESULTS: A total of 100 patients were enrolled at eight Canadian sites. The in-stent MLD at eight months was 2.46 ± 0.37 mm in the SES compared with 1.49 ± 0.75 mm in the BMS (a 65% increase, p < 0.001). Angiographic restenosis occurred in 1 of 44 SES patients (2.3%, with no in-stent restenosis) and in 23 of 44 BMS patients (52.3%, p < 0.001). At 270 days, there were two clinically driven TLRs in the SES (4%) and nine in the BMS (18%, p = 0.05). The Kaplan-Meier estimate of freedom from MACE at 270 days was 96.0% for SES patients and 81.7% for BMS patients (p = 0.029).
CONCLUSIONS: Patients with long lesions in small vessels are at very high risk of restenosis. In these patients, the SES dramatically reduces the risk of restenosis at eight months, translating into an excellent clinical outcome at nine months.
|
Abbreviations and Acronyms
| | BMS | = bare metal stent | | ISR | = in-stent restenosis | | MACE | = major adverse cardiac events | | MLD | = minimal lumen diameter | | PCI | = percutaneous coronary intervention | | QCA | = quantitative coronary angiography | | SES | = sirolimus-eluting stent | | TLR | = target lesion revascularization |
|
This article has been cited by other articles:
|
|
|
|
 
H. Ishii, Y. Kumada, T. Toriyama, T. Aoyama, H. Takahashi, T. Amano, Y. Yasuda, Y. Yuzawa, S. Maruyama, S. Matsuo, et al.
Aortic valvular calcification predicts restenosis after implantation of drug-eluting stents in patients on chronic haemodialysis
Nephrol. Dial. Transplant.,
December 15, 2008;
(2008)
gfn685v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/writing members, J. Daemen, M. L. Simoons, W. Wijns, A. Bagust, G. Bos, J. M. Bowen, E. Braunwald, E. Camenzind, B. Chevalier, et al.
Meeting Report * ESC Forum on Drug Eluting Stents * European Heart House, Nice, 27-28 September 2007
Eur. Heart J.,
November 26, 2008;
(2008)
ehn510v1.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Austin, K. G. Oldroyd, A. McConnachie, R. Slack, H. Eteiba, A. D. Flapan, K. P. Jennings, R. J. Northcote, A. C.H. Pell, I. R. Starkey, et al.
Drug-Eluting Stents Versus Bare-Metal Stents for Off-Label Indications: A Propensity Score-Matched Outcome Study
Circ Cardiovasc Intervent,
August 1, 2008;
1(1):
45 - 52.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. R. Brodie, T. Stuckey, W. Downey, A. Humphrey, B. Bradshaw, C. Metzger, J. Hermiller, F. Krainin, S. Juk, B. Cheek, et al.
Outcomes and Complications With Off-Label Use of Drug-Eluting Stents: Results From the STENT (Strategic Transcatheter Evaluation of New Therapies) Group
J. Am. Coll. Cardiol. Intv.,
August 1, 2008;
1(4):
405 - 414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. T. Newsome, M. A. Kutcher, and R. L. Royster
Coronary Artery Stents: Part I. Evolution of Percutaneous Coronary Intervention
Anesth. Analg.,
August 1, 2008;
107(2):
552 - 569.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Mahmud, G. Bromberg-Marin, V. Palakodeti, L. Ang, D. Creanga, and A. N. DeMaria
Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis.
J. Am. Coll. Cardiol.,
June 24, 2008;
51(25):
2385 - 2395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G Raja and G. D Dreyfus
Current Status of Off-pump Coronary Artery Bypass Surgery
Asian Cardiovasc Thorac Ann,
April 1, 2008;
16(2):
164 - 178.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Kip, K. Hollabaugh, O. C. Marroquin, and D. O. Williams
The Problem With Composite End Points in Cardiovascular Studies The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention.
J. Am. Coll. Cardiol.,
February 19, 2008;
51(7):
701 - 707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jeremias and A. Kirtane
Balancing Efficacy and Safety of Drug-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention
Ann Intern Med,
February 5, 2008;
148(3):
234 - 238.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. G. Nuhrenberg, N. Langwieser, J. B.K. Schwarz, Y. Hou, P. Frank, F. Sorge, S. Matschurat, S. Seidl, A. Kastrati, A. Schomig, et al.
EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury
Cardiovasc Res,
February 1, 2008;
77(3):
580 - 589.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. C. Marroquin, F. Selzer, S. R. Mulukutla, D. O. Williams, H. A. Vlachos, R. L. Wilensky, J.-F. Tanguay, E. M. Holper, J. D. Abbott, J. S. Lee, et al.
A Comparison of Bare-Metal and Drug-Eluting Stents for Off-Label Indications
N. Engl. J. Med.,
January 24, 2008;
358(4):
342 - 352.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
American College of Cardiology/American Heart Asso, 2007 Writing Group to Review New Evidence and Upda, S. B. King III, S. C. Smith Jr, J. W. Hirshfeld Jr, A. K. Jacobs, D. A. Morrison, and D. O. Williams
2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention
J. Am. Coll. Cardiol.,
January 15, 2008;
51(2):
172 - 209.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. King III, S. C. Smith Jr, J. W. Hirshfeld Jr, A. K. Jacobs, D. A. Morrison, D. O. Williams, 2005 WRITING COMMITTEE MEMBERS, S. C. Smith Jr, T. E. Feldman, J. W. Hirshfeld Jr, et al.
2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee
Circulation,
January 15, 2008;
117(2):
261 - 295.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Pocock, A. J. Lansky, R. Mehran, J. J. Popma, M. P. Fahy, Y. Na, G. Dangas, J. W. Moses, T. Pucelikova, D. E. Kandzari, et al.
Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials.
J. Am. Coll. Cardiol.,
January 1, 2008;
51(1):
23 - 32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Wilson and J. T. Willerson
Myocardial Revascularization with Percutaneous Devices
Card. Surg. Adult,
January 1, 2008;
3(2008):
573 - 598.
[Full Text]
|
|
|
|
|
|
|
E. Solinas, E. Nikolsky, A. J. Lansky, A. J. Kirtane, M.-C. Morice, J. J. Popma, J. Schofer, E. Schampaert, T. Pucelikova, J. Aoki, et al.
Gender-Specific Outcomes After Sirolimus-Eluting Stent Implantation
J. Am. Coll. Cardiol.,
November 27, 2007;
50(22):
2111 - 2116.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-C. Morice, P. W. Serruys, P. Barragan, C. Bode, G.-A. Van Es, H.-P. Stoll, D. Snead, L. Mauri, D. E. Cutlip, and E. Sousa
Long-Term Clinical Outcomes With Sirolimus-Eluting Coronary Stents: Five-Year Results of the RAVEL Trial
J. Am. Coll. Cardiol.,
October 2, 2007;
50(14):
1299 - 1304.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Simonton, B. Brodie, B. Cheek, F. Krainin, C. Metzger, J. Hermiller, S. Juk, P. Duffy, A. Humphrey, M. Nussbaum, et al.
Comparative Clinical Outcomes of Paclitaxel- and Sirolimus-Eluting Stents: Results From a Large Prospective Multicenter Registry STENT Group
J. Am. Coll. Cardiol.,
September 25, 2007;
50(13):
1214 - 1222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bode and M. Zehender
The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis
Eur. Heart J. Suppl.,
August 1, 2007;
9(suppl_D):
D10 - D19.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Vermeersch, P. Agostoni, S. Verheye, P. Van den Heuvel, C. Convens, F. Van den Branden, G. Van Langenhove, and DELAYED RRISC (Death and Events at Long-term follo
Increased Late Mortality After Sirolimus-Eluting Stents Versus Bare-Metal Stents in Diseased Saphenous Vein Grafts: Results From the Randomized DELAYED RRISC Trial
J. Am. Coll. Cardiol.,
July 17, 2007;
50(3):
261 - 267.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Daemen and P. W. Serruys
Drug-Eluting Stent Update 2007: Part I: A Survey of Current and Future Generation Drug-Eluting Stents: Meaningful Advances or More of the Same?
Circulation,
July 17, 2007;
116(3):
316 - 328.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Moreno, C. Fernandez, A. Sanchez-Recalde, G. Galeote, L. Calvo, F. Alfonso, R. Hernandez, R. Sanchez-Aquino, D. J. Angiolillo, S. Villarreal, et al.
Clinical impact of in-stent late loss after drug-eluting coronary stent implantation
Eur. Heart J.,
July 1, 2007;
28(13):
1583 - 1591.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. Stone, S. G. Ellis, A. Colombo, K. D. Dawkins, E. Grube, D. E. Cutlip, M. Friedman, D. S. Baim, and J. Koglin
Offsetting Impact of Thrombosis and Restenosis on the Occurrence of Death and Myocardial Infarction After Paclitaxel-Eluting and Bare Metal Stent Implantation
Circulation,
June 5, 2007;
115(22):
2842 - 2847.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H Wong, S. Wan, and M. J Underwood
Myocardial Revascularization: Surgery or Stenting?
Asian Cardiovasc Thorac Ann,
June 1, 2007;
15(3):
264 - 269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Rinfret and E. Schampaert
Drug-eluting stents
Can. Med. Assoc. J.,
May 22, 2007;
176(11):
1611 - 1612.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Beohar, C. J. Davidson, K. E. Kip, L. Goodreau, H. A. Vlachos, S. N. Meyers, K. H. Benzuly, J. D. Flaherty, M. J. Ricciardi, C. L. Bennett, et al.
Outcomes and Complications Associated With Off-Label and Untested Use of Drug-Eluting Stents
JAMA,
May 9, 2007;
297(18):
1992 - 2000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Camenzind, P. G. Steg, and W. Wijns
A Cause for Concern
Circulation,
March 20, 2007;
115(11):
1440 - 1455.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Spaulding, J. Daemen, E. Boersma, D. E. Cutlip, and P. W. Serruys
A Pooled Analysis of Data Comparing Sirolimus-Eluting Stents with Bare-Metal Stents
N. Engl. J. Med.,
March 8, 2007;
356(10):
989 - 997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. W. Stone, J. W. Moses, S. G. Ellis, J. Schofer, K. D. Dawkins, M.-C. Morice, A. Colombo, E. Schampaert, E. Grube, A. J. Kirtane, et al.
Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents
N. Engl. J. Med.,
March 8, 2007;
356(10):
998 - 1008.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kastrati, J. Mehilli, J. Pache, C. Kaiser, M. Valgimigli, H. Kelbaek, M. Menichelli, M. Sabate, M. J. Suttorp, D. Baumgart, et al.
Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents
N. Engl. J. Med.,
March 8, 2007;
356(10):
1030 - 1039.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Mauri, W.-h. Hsieh, J. M. Massaro, K. K.L. Ho, R. D'Agostino, and D. E. Cutlip
Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents
N. Engl. J. Med.,
March 8, 2007;
356(10):
1020 - 1029.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-P. B.-L. Rocca, C. Kaiser, M. Pfisterer, and on behalf of the BASKET Investigators
Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET)
Eur. Heart J.,
March 2, 2007;
28(6):
719 - 725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Valgimigli, K. Dawkins, C. Macaya, B. de Bruyne, E. Teiger, J. Fajadet, R. Gert, S. De Servi, A. Ramondo, K. Wittebols, et al.
Impact of Stable Versus Unstable Coronary Artery Disease on 1-Year Outcome in Elective Patients Undergoing Multivessel Revascularization With Sirolimus-Eluting Stents: A Subanalysis of the ARTS II Trial
J. Am. Coll. Cardiol.,
January 30, 2007;
49(4):
431 - 441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ligthart, F. Vlemmix, N. Dendukuri, and J. M. Brophy
The cost-effectiveness of drug-eluting stents: a systematic review
Can. Med. Assoc. J.,
January 16, 2007;
176(2):
199 - 205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Kandzari, M. B. Leon, J. J. Popma, P. J. Fitzgerald, C. O'Shaughnessy, M. W. Ball, M. Turco, R. J. Applegate, P. A. Gurbel, M. G. Midei, et al.
Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients With Native Coronary Artery Disease: A Randomized Controlled Trial
J. Am. Coll. Cardiol.,
December 19, 2006;
48(12):
2440 - 2447.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Vermeersch, P. Agostoni, S. Verheye, P. Van den Heuvel, C. Convens, N. Bruining, F. Van den Branden, and G. Van Langenhove
Randomized Double-Blind Comparison of Sirolimus-Eluting Stent Versus Bare-Metal Stent Implantation in Diseased Saphenous Vein Grafts: Six-Month Angiographic, Intravascular Ultrasound, and Clinical Follow-Up of the RRISC Trial
J. Am. Coll. Cardiol.,
December 19, 2006;
48(12):
2423 - 2431.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Nordmann, M. Briel, and H. C. Bucher
Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis
Eur. Heart J.,
December 1, 2006;
27(23):
2784 - 2814.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. R. Holmes Jr, J. W. Moses, J. Schofer, M.-C. Morice, E. Schampaert, and M. B. Leon
Cause of death with bare metal and sirolimus-eluting stents
Eur. Heart J.,
December 1, 2006;
27(23):
2815 - 2822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. O. Williams, J. D. Abbott, K. E. Kip, and for the DEScover Investigators
Outcomes of 6906 Patients Undergoing Percutaneous Coronary Intervention in the Era of Drug-Eluting Stents: Report of the DEScover Registry
Circulation,
November 14, 2006;
114(20):
2154 - 2162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Corbett, J. Cosgrave, G. Melzi, R. Babic, G. G.L. Biondi-Zoccai, C. Godino, N. Morici, F. Airoldi, I. Michev, M. Montorfano, et al.
Patterns of restenosis after drug-eluting stent implantation: insights from a contemporary and comparative analysis of sirolimus- and paclitaxel-eluting stents
Eur. Heart J.,
October 1, 2006;
27(19):
2330 - 2337.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Futamatsu, M. Sabate, D. J. Angiolillo, P. Jimenez-Quevedo, C. Corros, K. Morikawa-Futamatsu, F. Alfonso, J. Jiang, P. Cervinka, R. Hernandez-Antolin, et al.
Characterization of Plaque Prolapse After Drug-Eluting Stent Implantation in Diabetic Patients: A Three-Dimensional Volumetric Intravascular Ultrasound Outcome Study
J. Am. Coll. Cardiol.,
September 19, 2006;
48(6):
1139 - 1145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Suttorp, G. J. Laarman, B. M. Rahel, J. C. Kelder, M. A.R. Bosschaert, F. Kiemeneij, J. M. ten Berg, E. T. Bal, B. J. Rensing, F. D. Eefting, et al.
Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): A Randomized Comparison of Bare Metal Stent Implantation With Sirolimus-Eluting Stent Implantation for the Treatment of Total Coronary Occlusions
Circulation,
August 29, 2006;
114(9):
921 - 928.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Kereiakes, H. Wang, J. J. Popma, R. E. Kuntz, D. J. Donohoe, J. Schofer, E. Schampaert, B. Meier, M. B. Leon, and J. W. Moses
Periprocedural and Late Consequences of Overlapping Cypher Sirolimus-Eluting Stents: Pooled Analysis of Five Clinical Trials
J. Am. Coll. Cardiol.,
July 4, 2006;
48(1):
21 - 31.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Joner, A. V. Finn, A. Farb, E. K. Mont, F. D. Kolodgie, E. Ladich, R. Kutys, K. Skorija, H. K. Gold, and R. Virmani
Pathology of Drug-Eluting Stents in Humans: Delayed Healing and Late Thrombotic Risk
J. Am. Coll. Cardiol.,
July 4, 2006;
48(1):
193 - 202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Cosgrave, G. Melzi, G. G.L. Biondi-Zoccai, F. Airoldi, A. Chieffo, G. M. Sangiorgi, M. Montorfano, I. Michev, M. Carlino, E. Bonizzoni, et al.
Drug-Eluting Stent Restenosis: The Pattern Predicts the Outcome
J. Am. Coll. Cardiol.,
June 20, 2006;
47(12):
2399 - 2404.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Roiron, P Sanchez, A Bouzamondo, P Lechat, and G Montalescot
Drug eluting stents: an updated meta-analysis of randomised controlled trials
Heart,
May 1, 2006;
92(5):
641 - 649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Stettler, S Allemann, M Egger, S Windecker, B Meier, and P Diem
Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials
Heart,
May 1, 2006;
92(5):
650 - 657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Rodriguez, J. F. Granada, M. Rodriguez-Alemparte, C. F. Vigo, J. Delgado, C. Fernandez-Pereira, A. Pocovi, A. M. Rodriguez-Granillo, D. Schulz, A. E. Raizner, et al.
Oral Rapamycin After Coronary Bare-Metal Stent Implantation to Prevent Restenosis: The Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study
J. Am. Coll. Cardiol.,
April 18, 2006;
47(8):
1522 - 1529.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Weisz, M. B. Leon, D. R. Holmes Jr, D. J. Kereiakes, M. R. Clark, B. M. Cohen, S. G. Ellis, P. Coleman, C. Hill, C. Shi, et al.
Two-Year Outcomes After Sirolimus-Eluting Stent Implantation: Results From the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) Trial
J. Am. Coll. Cardiol.,
April 4, 2006;
47(7):
1350 - 1355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Urban, A. H. Gershlick, G. Guagliumi, P. Guyon, C. Lotan, J. Schofer, A. Seth, J. E. Sousa, W. Wijns, C. Berge, et al.
Safety of Coronary Sirolimus-Eluting Stents in Daily Clinical Practice: One-Year Follow-Up of the e-Cypher Registry
Circulation,
March 21, 2006;
113(11):
1434 - 1441.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
